To view enhanced content go to www.biologicstherapy-open.com
This article is published with open access at Springerlink.com
Pompe’s disease is a metabolic myopathy caused by a deficiency of the enzyme alpha-glucosidase. Patients with late-onset Pompe’s disease have progressive muscle weakness, which also affects pulmonary function. Since the advent of specific treatment for Pompe’s disease, enzyme replacement therapy with alpha-glucosidase, the prognosis of the disease has changed.
We report the case of the first patient treated in Spain with home therapy, and the effects on her clinical status of a reduction in treatment frequency.
A worsening was seen in the patient’s neuromuscular assessment on different scales, after two discontinuations during the patient’s usual administration frequency.
It is essential to keep an adequate administration schedule to maintain the clinical benefits of enzyme therapy.
Pompe JC. Over idiopatische hypertrophie van het hart. Ned Tijdshr Geneeskd. 1932;76:304.
Hers, HG. α-Glucosidase deficiency in generalized glycogen storage disease (Pompe’s disease). Biochem J. 1963:86:11–16. PubMed
Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York. 2001. pp 3389–420.
Wolfgang Muller-Felber, Rita Horvath, Klaus Gempel, et al. Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Dis. 2007:17;698–706. CrossRef
Medical Research Council. Aids to the examination of the peripheral nervous system, Memorandum no. 45, Her Majesty’s Stationery Office, London, 1981.
Hamilton BB, Laughlin JA, Fiedler RC, Granger CV. Interrater reliability of the 7-level functional independence measure (FIM). Scand J Rehabil Med. 1994;26:115–119. PubMed
Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid-glucosidase. Major clinical benefits in infantile-onset Pompe disease. Neurol. 2007;68:99–109. CrossRef
Van der Ploeg A, Marsden DL. Response to enzyme replacement therapy in 18 juvenile and adult patients with severe Pompe disease. Mol Genet Metabol. 2007;90:227–265. CrossRef
Van der Ploeg A, Clemens PR, Corzo D, et al. A randomized study of Alglucosidase alfa in late-onset Pompe’s disease. N Eng J Med. 2010:362;1396–1406. CrossRef
- Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe’s disease
Emilia Barrot Cortés
Juana María Barrera Chacón
- Springer Healthcare Communications
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II